Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo-Reference-Cited by-同舟云学术

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

Published:2015-04 Issue:4 Volume:27 Page:473-488
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Roghanian Ali,Teige Ingrid,Mårtensson Linda,Cox Kerry L.,Kovacek Mathilda,Ljungars Anne,Mattson Jenny,Sundberg Annika,Vaughan Andrew T.,Shah Vallari,Smyth Neil R.,Sheth Bhavwanti,Chan H.T. Claude,Li Zhan-Chun,Williams Emily L.,Manfredi Giusi,Oldham Robert J.,Mockridge C. Ian,James Sonya A.,Dahal Lekh N.,Hussain Khiyam,Nilsson Björn,Verbeek J. Sjef,Juliusson Gunnar,Hansson Markus,Jerkeman Mats,Johnson Peter W.M.,Davies Andrew,Beers Stephen A.,Glennie Martin J.,Frendéus Björn,Cragg Mark S.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference44 articles.

1. Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo;Baerenwaldt;Proc. Natl. Acad. Sci. USA,2011

2. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer;Bardelli;J. Clin. Oncol.,2010

3. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation;Beers;Blood,2008

4. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection;Beers;Blood,2010

5. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo;Biburger;Immunity,2011

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies;Frontiers in Oncology;2024-09-02

3. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies;Drug Development Research;2024-09

4. Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia;Leukemia Research;2024-08

5. Insights into the role of derailed endocytic trafficking pathway in cancer: From the perspective of cancer hallmarks;Pharmacological Research;2024-03